Table 1 Baseline characteristics between controls and CRC patients
Characteristic | Controls (n = 399) | CRC Patients (n = 472) | P | Colon cancer (n = 268) | P | Rectal cancer (n = 193) | P |
|---|---|---|---|---|---|---|---|
Age (years, mean ± SD) | 61.15 ± 10.93 | 61.99 ± 12.32 | 0.129 | 61.44 ± 12.88 | 0.464 | 62.28 ± 11.54 | 0.153 |
Male (%) | 173 (43.4) | 212 (44.9) | 0.645 | 118 (44.0) | 0.915 | 88 (45.6) | 0.750 |
Hypertension (%) | 155 (38.8) | 281 (59.5) | < 0.0001 | 157 (58.6) | 0.003 | 117 (60.6) | 0.003 |
HDL-C (mg/dL, mean ± SD) | 45.91 ± 13.48 | 42.18 ± 13.05 | 0.001 | 42.82 ± 13.00 | 0.013 | 41.27 ± 13.07 | 0.001 |
LDL-C (mg/dL, mean ± SD) | 115.87 ± 40.28 | 101.31 ± 28.62 | 0.003 | 98.55 ± 28.01 | 0.002 | 104.32 ± 29.54 | 0.142 |
Diabetes mellitus (%) | 52 (13.0) | 156 (33.1) | < 0.0001 | 92 (34.3) | < 0.0001 | 64 (33.2) | < 0.0001 |
Smoking (%) | 138 (34.6) | 92 (19.5) | < 0.0001 | 55 (20.5) | 0.003 | 35 (18.1) | 0.002 |
Folate (nmol/L, mean ± SD) | 8.64 ± 6.13 | 7.94 ± 7.13 | < 0.0001 | 8.12 ± 7.36 | 0.001 | 7.70 ± 6.86 | 0.000 |
Triglyceride (mg/dL, mean ± SD) | 146.79 ± 89.33 | 129.00 ± 86.30 | 0.0003 | 126.93 ± 84.48 | 0.001 | 132.48 ± 90.86 | 0.015 |
Homocysteine (μmol/L, mean ± SD) | 9.96 ± 4.27 | 10.68 ± 7.83 | 0.671 | 10.47 ± 8.21 | 0.572 | 10.88 ± 7.32 | 0.215 |
Total cholesterol (mg/dL, mean ± SD) | 192.00 ± 37.32 | 178.76 ± 40.56 | 0.0001 | 178.73 ± 38.88 | 0.001 | 176.69 ± 42.89 | 0.002 |
Tumor size (%) | |||||||
  < 5 cm |  | 208 (44.1) |  | 106 (39.6) |  | 93 (48.2) |  |
  ≥ 5 cm | 264 (55.9) | 162 (60.4) | 100 (51.8) | ||||
TNM stage (%) | |||||||
 I |  | 52 (11.2) |  | 26 (9.7) |  | 26 (13.5) |  |
 II | 191 (41.0) | 118 (44.2) | 70 (36.3) | ||||
 III | 176 (37.8) | 94 (35.2) | 81 (42.0) | ||||
 IV | 47 (10.1) | 29 (10.9) | 16 (8.3) | ||||
 N.A. | 6 | 1 | 0 | ||||
MSI (%) | 61 (15.6) | 49 (22.0) | 12 (7.3) | ||||
 MSI-high (%) | 46 (11.8) | 38 (17.0) | 8 (4.9) | ||||
 MSI-low (%) | 15 (3.8) | 11 (4.9) | 4 (2.4) | ||||
 N.A. | 82 | 45 | 29 | ||||